Skip to main content
Premium Trial:

Request an Annual Quote

New Products: GeneDx's Mito101

Premium

GeneDx has launched Mito101, a sequencing-based diagnostic that targets 101 nuclear genes associated with mitochondrial disorders. The test expands on the company's current Mito24 test, which targets just 24 genes.

Mito101 targets 1,000 exons from 101 genes and disease-associated variants are verified with Sanger sequencing. It has a turnaround time of around 10 weeks and a contract price of $6,500.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.